Chelsea Counsel Company’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Chelsea Counsel Company’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-650	Closed	-$3K	–	89
2016 Q3	$3K	Hold	650	–	–	﹤0.01%	88
2016 Q2	$6K	Sell	650 -50	-7%	-$514	﹤0.01%	95
2016 Q1	$8K	Hold	700	–	–	﹤0.01%	126
2015 Q4	$10K	Hold	700	–	–	﹤0.01%	135
2015 Q3	$12K	Hold	700	–	–	﹤0.01%	156
2015 Q2	$13K	Hold	700	–	–	﹤0.01%	159
2015 Q1	$14K	Hold	700	–	–	﹤0.01%	137
2014 Q4	$20K	Hold	700	–	–	﹤0.01%	134
2014 Q3	$25K	Hold	700	–	–	0.01%	131
2014 Q2	$31K	Hold	700	–	–	0.01%	124
2014 Q1	$34K	Hold	700	–	–	0.01%	121
2013 Q4	$26K	Hold	700	–	–	0.01%	110
2013 Q3	$72K	Hold	700	–	–	0.01%	111
2013 Q2	$54K	Buy	+700	New	+$67K	0.01%	101

Other funds holding IMUC

Sabby Management Miami Beach, Florida $5.71M AUM 74.25% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return